The short version of DAC linker fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
As of June 2021, Sputnik V is under rolling review process by EMA, but the marketing authorisation application was not submitted yet. Emergency use has also been authorized in Algeria, Bolivia, Serbia, the Palestinian territories, and Mexico. On 25 January 2021, Iran approved the vaccine, with Foreign Minister Mohammad Javad Zarif saying the country hopes to begin purchases and start joint production of the shot "in the near future", after Supreme Leader Ayatollah Ali Khamenei banned the government from importing vaccines from the United States and United Kingdom. The Czech Republic was also considering buying Sputnik V, and Prime Minister Andrej Babis dismissed the Minister of Health, Jan Blatný, who was a loud opponent to the use of Sputnik V. On 4 March 2021, EMA's human medicines committee (CHMP) has started a rolling review of Sputnik V (Gam-COVID-Vac), a COVID-19 vaccine developed by Russia's Gamaleya National Centre of Epidemiology and Microbiology. When asked about the prospect of Austria giving Sputnik V the approval (as some other European countries chose to do), EMA management board chair Christa Wirthumer-Hoche pointed to the fact there was not yet sufficient safety data about those who had already been given the vaccine. "We could have Sputnik V on the market in future, when we've examined the necessary data," she said, adding that the vaccine needed to match up to European criteria on quality control and efficacy.
=== Sri Lankan === Soy sauce (Sinhala: සෝයා සෝස්) is a popular food product used in Sri Lanka and is a major ingredient used in the nationally popular street food dish kottu. Soy sauce has largely been produced by the Sri Lankan Chinese community but its production has also spread to other communities in Sri Lanka. Soy sauce production in Sri Lanka is the same as the production of soy sauce in Indonesia. Fermentation occurs over a period of three months. The soy beans which are steeped in brine are then pressed to obtain a liquid sauce.
=== Monocyte activation test === The monocyte activation test (MAT) uses the monocytes in human blood in vitro to detect pyrogens. It was added to the European Pharmacopoeia in 2010 and accepted by the FDA in 2012.
In 2005, Essendon missed the finals for the first time since 1997, and in 2006, despite a first-round 27-point thrashing of defending premiers Sydney in which newly appointed captain Matthew Lloyd kicked eight goals playing on Leo Barry, shortly after which he suffered a season-ending hamstring injury, the Bombers were uncompetitive for the majority of the season, recording only three wins and one draw from twenty-two games to suffer its worst season since 1933. In Lloyd's absence, David Hille was appointed captain for the remainder of the season. The club improved its on-field position in 2007 but again missed the finals.
Sources: en.wikipedia.org
== Adverse effects == GLP-1 agonists' most common adverse effects are gastrointestinal. These limit the maximum tolerated dose and require gradual dose escalation. Nausea, vomiting, diarrhea, and constipation are commonly reported. Nausea is directly related to serum concentration and is reported in up to three-quarters of people using short-acting GLP-1 agonists, but fewer of those using long-acting agonists. Injection site reactions are common, especially with shorter-acting drugs. GLP-1 agonists appear to increase the risk of non-arteritic anterior ischemic optic neuropathy. Some people develop anti-drug antibodies, which are more common with exenatide (the antibodies were detectable in a third or more of people) than other GLP-1 agonists and can decrease efficacy. Gallstones may form while attempting to induce rapid weight loss. The risk of aspiration under anesthesia is higher due to delayed gastric emptying, according to case reports. In 2024, the American Society of Anesthesiologists and others suggested suspending GLP-1 agonist treatment in most people on the day of the procedure for daily dosing or a week before for weekly dosing. A 2024 study suggested that GLP-1 weight-loss medications do not increase the risk of suicide or suicidal thoughts in children and adolescents, contrary to some previous concerns. The study included over 54,000 U.S. adolescents and reported a 33% reduction in the risk of suicidal thoughts and attempts among those using the drugs compared to those who did not.
== Function in Disease and Immunity and Clinical Relevance == Reticular cells do far more than support immune cells. They actively shape immune responses during disease and repair. As mentioned previously, their combined role in structure and signaling makes them crucial in both innate and adaptive immunity. Li et al. (2021) explain that fibroblastic reticular cells in lymph nodes organize structure, recruit immune cells, and present antigens. Additionally, it has been shown that they also induce interactions between dendritic cells, macrophages, and lymphocytes. This type of organization performed by the reticular cells ensures that immune reactions occur in the correct sequence, facilitating that a proper response happens. In a pathological environment, reticular cells adapt to regulate inflammation and tissue remodeling. For instance, when in chronic infection or autoimmune disorders, delayed activation of reticular cells can alter lymph node structure and either inhibit or intensify immune responses. Mueller and Germain (2015) found that excessive signaling from reticular cells contributes to immune dysregulation, leading to disorders in the body such as fibrosis. Conversely, it has been shown that controlled activation can actually enhance immune protection. Recent research also links fibroblastic reticular cells to anti-tumor immunity. In a 2025 Cell study, Onder et al. discovered that reticular cells located near tumors in lung cancer generate unique environments that allow cytotoxic T cells to infiltrate deeper into the cancer.
== Cause == Causes may include trauma or repetitive activities. Less common causes include infection, arthritis, gout, thyroid disease, and diabetes. Obesity, or more specifically, adiposity or fatness, is linked to increasing incidence of tendinopathy. Quinolone antibiotics are associated with increased risk of tendinitis and tendon rupture. A 2013 review found the incidence of tendon injury among those taking fluoroquinolones to be between 0.08 and 0.2%. Fluoroquinolones most frequently affect large load-bearing tendons in the lower limb, especially the Achilles tendon.
=== General references === Daxer, Albert; Misof, Klaus; Grabner, Barbara; Ettl, Armin; Fratzl, Peter (1998). "Collagen fibrils in the human corneal stroma: Structure and aging". Investigative Ophthalmology & Visual Science. 39 (3): 644–8. PMID 9501878. Daxer, Albert; Fratzl, Peter (1997). "Collagen fibril orientation in the human corneal stroma and its implication in keratoconus". Investigative Ophthalmology & Visual Science. 38 (1): 121–9. PMID 9008637. Fratzl, Peter; Daxer, Albert (1993). "Structural transformation of collagen fibrils in corneal stroma during drying. An x-ray scattering study". Biophysical Journal. 64 (4): 1210–4. Bibcode:1993BpJ....64.1210F. doi:10.1016/S0006-3495(93)81487-5. PMC 1262438. PMID 8494978.
=== Kniest dysplasia === Most mutations responsible for Kniest dysplasia result in abnormally short pro-alpha1(II) collagen chains that combine with normal-length chains, producing shorter-than-normal collagen molecules. This results in the characteristic features of Kniest dysplasia.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.